Jan 2023 – Present · 3 yrs 3 mos

Jan 2023 – Present · 3 yrs 3 mos

• Cambridge Enterprise is responsible for supporting the translation of Cambridge University research to create globally leading economic and social impact.

Jan 2023 – Present · 3 yrs 3 mos

• RAND is a research organization that develops solutions to public policy challenges to help make communities throughout the world safer and more secure, healthier and more prosperous. RAND is nonprofit, nonpartisan, and committed to the public interest.

Jan 2022 – Present · 4 yrs 3 mos

• Lindus Health is reshaping clinical trial delivery by vertically integrating an eClinical platform with full-service CRO capabilities. Rather than just providing software alongside traditional infrastructure, they're managing the entire process—from site identification through to regulatory submission. What makes this compelling is their speed: they're consistently delivering trials in half the time of traditional CROs by removing friction between disparate systems and vendors, directly addressing one of drug development's most persistent bottlenecks.

Jan 2022 – Present · 4 yrs 3 mos

Jan 2022 – Present · 4 yrs 3 mos · San Francisco, London

• I founded Recode Ventures to back the new wave of scientific and technological disruption—because this time, the change isn’t incremental. It’s exponential.
• It’s not just AI. It’s the compound acceleration of compute, biology, and data—stacking like Moore’s Law in parallel. The outcomes are unpredictable. The opportunities are unprecedented.
• Recode Ventures invests at pre-seed, seed, and Series A. We partner early with founders building companies that will define the future.

Jan 2021 – Present · 5 yrs 3 mos

• Relation Therapeutics is reimagining drug discovery by integrating human genetics with single-cell biology and machine learning to identify disease mechanisms at unprecedented resolution. Rather than relying on traditional model systems, they use patient-derived cells combined with genetic data to understand exactly which cell types and pathways drive disease, then validate these insights computationally before entering the lab. This genetics-first approach significantly de-risks target selection—genetically validated targets have roughly twice the clinical success rate—while their single-cell platform reveals therapeutic opportunities that would be invisible in bulk tissue analysis.

Jan 2021 – Jan 2023 · 2 yrs

Jan 2020 – Present · 6 yrs 3 mos · Oxford, England, United Kingdom

Jan 2020 – Present · 6 yrs 3 mos · United Kingdom

Jan 2019 – Jan 2023 · 4 yrs · Oxford, United Kingdom

Jan 2019 – Aug 2022 · 3 yrs 7 mos · London, United Kingdom

May 2018 – Aug 2018 · 3 mos · United Kingdom

Jan 2018 – Present · 8 yrs 3 mos

• Turbine is reimagining oncology drug discovery by creating computational models that simulate cancer biology at a molecular level. Rather than traditional trial-and-error screening, they build "digital twins" of cancer cells to predict how tumors will respond to different treatments and identify non-obvious drug combinations before entering the lab. This simulation-first approach allows them to discover therapeutic strategies—particularly combination therapies—that would be nearly impossible to find through conventional methods, while dramatically reducing the time and cost of bringing new cancer treatments to patients.

Jan 2018 – Present · 8 yrs 3 mos · Cambridge, United Kingdom

Jan 2018 – Present · 8 yrs 3 mos · Cambridge, United Kingdom

Jan 2018 – Present · 8 yrs 3 mos · London, United Kingdom

Jan 2018 – Jan 2023 · 5 yrs · Cambridge, United Kingdom

Jan 2018 – Jan 2021 · 3 yrs · Oxford, United Kingdom

• Independent non executive director on the board of Sensyne Health plc which is building a new business model for using patient data to build novel treatments using machine learning and artificial intelligence.

Jan 2017 – Present · 9 yrs 3 mos · London, United Kingdom

• Zoe is transforming personalized nutrition by combining gut microbiome testing, continuous glucose monitoring, and machine learning to provide individualized dietary recommendations. Backed by the PREDICT studies—the largest nutrition research program of its kind—they're demonstrating that metabolic responses to identical foods vary dramatically between individuals, challenging traditional one-size-fits-all dietary guidance.

Jan 2017 – Present · 9 yrs 3 mos · London, United Kingdom

Jan 2017 – May 2023 · 6 yrs 4 mos · Oxford, United Kingdom

Jan 2017 – Jan 2023 · 6 yrs · Cambridge, United Kingdom

Jan 2017 – Jan 2021 · 4 yrs · Stockholm, Sweden

Apr 2016 – Present · 10 yrs · India

• CONTINUA Kids (Centre of Neurotherapy In Uniquely-Abled Kids) is a cutting-edge, research-driven, and holistic online center dedicated to providing exceptional therapies, early intervention programs, and unwavering support for uniquely-abled children. What sets us apart is our ability to deliver all the scientifically proven, individualized therapies required for special children through convenient online platforms. Discover the transformative power of online therapies and support for your child's development from the comfort of your own home.

Jan 2016 – Jan 2023 · 7 yrs

Jan 2016 – Jan 2021 · 5 yrs · Manchester, United Kingdom

Jan 2013 – May 2023 · 10 yrs 4 mos · London, United Kingdom

• I am responsible for healthcare deals at Draper Esprit plc, a listed Patient Capital VC firm. Draper Esprit is a member of the Draper Venture Network, the largest venture capital network in the world with 140 investment professionals and over 600 portfolio companies.
• My specific interest is healthcare businesses which have the potential to leverage the power of data and/or connectivity to make significant improvement in patient experience and outcome and can scale globally. These deals can be primary or secondary.

Jan 2013 – Jan 2021 · 8 yrs · Cambridge, United Kingdom

• Horizon Discovery Limited (Horizon) is a leading translational genomics and gene editing company which delivers technology solutions for research and the development of personalized medicines. Listed on the London Stock Exchange
• Queen’s Award for Enterprise in International trade in 2012
• Best Cancer Discovery Technology and Best Business Proposition at the Medical Futures Innovation Awards (2008);
• Best Technology Start-Up and Best Company at iAwards (2009); Killer Technology Company (2009)
• Best Young Company (2010) and Best Company (2011) at the East of England Business Awards;
• Best Licensing Deal of the Year at the Scrip Awards (2013);
• Most Promising Company at the Personalised Medicine World Congress (2013).

Jan 2012 – Present · 14 yrs 3 mos · London, San Francisco, Berlin, Stockholm, Cambridge · Hybrid

• Venture Capital investor Investing in the convergence of digital/AI and healthcare.
• Portfolio of over 20 companies in UK, Europe and USA
• Stage agnostic (early stage preferred)

Jan 2011 – Mar 2019 · 8 yrs 2 mos · London, United Kingdom

• Digital Health Forum supports evolving digital health ecosystem by promoting entrepreneurship, investment and partnering in the emerging sector
• www.digitalhealthforum.net

Jan 2010 – Jan 2019 · 9 yrs · London, United Kingdom

• Specialism: Technology impact on healthcare

Jan 2007 – Jan 2008 · 1 yr · Cambridge, United Kingdom

• Psynova Neurotech is exclusively focused on the commercial development and exploitation of novel biomarkers for Neuropsychiatric and other mental illnesses.
• Winners of the Medical Futures Innovations Awards; Building on 12 years of ground-breaking research by its founder Prof. Sabine Bahn, Psynova Neurotech is initially concentrating on Schizophrenia and Bipolar Affective Disorder.” VeriPsych™ is the first and only blood test to aid a psychiatrist in the diagnosis of recent-onset schizophrenia. For more information visit the VeriPsych™ website.

Jan 2004 – Jan 2010 · 6 yrs · United Kingdom

Dec 2000 – Sep 2005 · 4 yrs 9 mos · Cambridge MA (USA)

• BioScale develops manufacture and promote a sophisticated protein measurement technology to accelerate drug discovery, development and production of biological and pharmaceutical products. The simplicity, power and speed of our innovative technology enables its customers to achieve major advancements in protein research that were not previously attainable by allowing the ultra-sensitive detection of proteins in multiple types of complex biological samples.

Oct 2000 – Sep 2003 · 2 yrs 11 mos

• Atlas Venture is an early stage venture capital fund that invests in promising entrepreneurs focusing on life sciences and technology innovation.

Jan 1997 – Jan 2000 · 3 yrs

• The Wellcome Trust is a global foundation dedicated to achieving extraordinary improvements in human and animal health.
• Wellcome supports the brightest minds in biomedical research and the medical humanities. Wellcome's breadth of support includes public engagement, education and the application of research to improve health.

Jan 1995 – Jan 1999 · 4 yrs